ERVEBO - EBOLA ZAIRE VACCINE: A TALE OF INNOVATION AND COLLABORATION

Date/Time: 01 April 2020, 12:00 PM - 1:00 PM
Speaker: Beth-Ann Coller, Ph.D.
Speaker Affiliation: Executive Director, Global Clinical Development, Merck Research Laboratories, North Wales, Pennsylvania
Venue: via Zoom link: https://hawaii.zoom.us/j/4234371004 or phone: (669) 900-6833 Zoom ID: 423 437 1004

For more info: Cori Watanabe, corit@hawaii.edu, (808) 692-1654
Description: Ebola continues to cause significant morbidity and mortality in regions of the world where the provision of healthcare and vaccine are difficult. The Merck vaccine is a live recombinant vesicular stomatitis virus (VSV) containing the Zaire Ebola virus glycoprotein (GP) in place of the VSV GP (rVSV<>G-ZEBOV-GP). Its safety, efficacy, or immunogenicity has been evaluated in 13 clinical trials, and the vaccine has been approved for use in humans by the European Medicines Agency, United States Food and Drug Administration, several African countries, and has been prequalified by the World Health Organization. More than 300,000 people have received the vaccine to date. Safety, immunogenicity, and efficacy data from across the program will be discussed as well as the use of the vaccine in the context of outbreak response.

Additional Document:Click here to download